Exane Derivatives boosted its holdings in Danaher Co. (NYSE:DHR – Get Rating) by 15.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,563 shares of the conglomerate’s stock after purchasing an additional 1,175 shares during the quarter. Danaher comprises 0.7% of Exane Derivatives’ investment portfolio, making the stock its 23rd largest holding. Exane Derivatives’ holdings in Danaher were worth $2,512,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the stock. JFS Wealth Advisors LLC raised its position in Danaher by 30.4% in the 4th quarter. JFS Wealth Advisors LLC now owns 150 shares of the conglomerate’s stock valued at $49,000 after purchasing an additional 35 shares during the last quarter. Cavalier Investments LLC grew its stake in shares of Danaher by 0.7% during the 4th quarter. Cavalier Investments LLC now owns 4,961 shares of the conglomerate’s stock worth $1,632,000 after purchasing an additional 36 shares during the period. Rossmore Private Capital grew its stake in Danaher by 0.6% in the 4th quarter. Rossmore Private Capital now owns 6,427 shares of the conglomerate’s stock valued at $2,115,000 after acquiring an additional 37 shares during the last quarter. US Asset Management LLC boosted its stake in shares of Danaher by 0.6% during the 1st quarter. US Asset Management LLC now owns 5,774 shares of the conglomerate’s stock worth $1,694,000 after purchasing an additional 37 shares during the last quarter. Finally, Dubuque Bank & Trust Co. lifted its holdings in shares of Danaher by 1.5% during the 4th quarter. Dubuque Bank & Trust Co. now owns 2,552 shares of the conglomerate’s stock worth $840,000 after acquiring an additional 38 shares during the period. Hedge funds and other institutional investors own 78.42% of the company’s stock.
Several analysts have issued reports on DHR shares. Robert W. Baird lowered their price objective on shares of Danaher from $334.00 to $319.00 and set an “outperform” rating for the company in a research report on Friday, April 22nd. UBS Group decreased their price objective on shares of Danaher from $365.00 to $340.00 in a report on Sunday, April 24th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Friday, April 22nd. Wells Fargo & Company cut Danaher from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $330.00 to $265.00 in a research note on Monday, April 25th. Finally, William Blair reiterated an “outperform” rating on shares of Danaher in a research note on Friday, April 22nd. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $336.08.
Danaher (NYSE:DHR – Get Rating) last issued its quarterly earnings results on Thursday, April 21st. The conglomerate reported $2.76 EPS for the quarter, topping the consensus estimate of $2.65 by $0.11. Danaher had a net margin of 21.32% and a return on equity of 18.64%. The firm had revenue of $7.69 billion for the quarter, compared to analysts’ expectations of $7.53 billion. During the same period in the previous year, the business earned $2.52 earnings per share. Danaher’s revenue for the quarter was up 11.6% compared to the same quarter last year. As a group, equities analysts anticipate that Danaher Co. will post 10.31 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Friday, June 24th will be paid a $0.25 dividend. The ex-dividend date of this dividend is Thursday, June 23rd. This represents a $1.00 dividend on an annualized basis and a yield of 0.39%. Danaher’s dividend payout ratio is currently 11.57%.
In other Danaher news, EVP Joakim Weidemanis sold 6,500 shares of Danaher stock in a transaction dated Monday, April 25th. The stock was sold at an average price of $255.74, for a total transaction of $1,662,310.00. Following the transaction, the executive vice president now owns 86,398 shares of the company’s stock, valued at approximately $22,095,424.52. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 11.20% of the company’s stock.
Danaher Profile (Get Rating)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy.
- Get a free copy of the StockNews.com research report on Danaher (DHR)
- Using MarketBeat Market Data Tools To Find Strong Stocks in a Bear Market
- Schnitzer Steel Witnesses A Strong Quarter On The Back Of Strong Domestic Demand
- MarketBeat: Week in Review 6/27 – 7/1
- Accolade Moves Higher But Growth Is Slowing
- ZIM Integrated Shipping Services (ZIM): Don’t Miss This Dividend
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.